|
64 Companies |
|
72 Products |
|
72 Products |
|
70 Mechanisms of Action |
|
1 Trial |
|
336 News |
|
| «1234567» |
- |||| saridegib oral (IPI 926 oral) / Infinity Pharma
Trial completion, Metastases: A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma (clinicaltrials.gov) - Dec 3, 2013
P2, N=105, Completed, Sponsor: Infinity Pharmaceuticals, Inc.
Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Nov 17, 2013
P2, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
- Enrollment closed: Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: National Cancer Center, Korea
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg.
New P1 trial: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Oct 23, 2013
P1, N=10, Recruiting, Sponsor: University of Louisville
- melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Oct 23, 2013
P1, N=10, Recruiting, Sponsor: University of Louisville
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- sirolimus / Generic mfg.
Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 10, 2013
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting N=20 --> 30
- Trial completion: Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=20, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
N=20 --> 30 Recruiting --> Completed
- | robatumumab (SCH 717454) / Merck (MSD)
Trial termination: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) (clinicaltrials.gov) - Sep 12, 2013
P2, N=219, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern.
- | Trial completion: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 12, 2013
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern. Active, not recruiting --> Completed
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment open, P1 data: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Aug 26, 2013
P1, N=20, Recruiting, Sponsor: NPM Pharma Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial termination, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2013
P2b, N=370, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III.
- TXA-127 / Constant Therap
Trial completion, Surgery, Metastases: Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jul 28, 2013
P2, N=20, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. Active, not recruiting --> Completed
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Trial initiation date: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=15, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Initiation date: Mar 2013 --> Jul 2013
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment open: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jul 23, 2013
P=N/A, N=15, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Mar 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
New P1 trial, P1 data: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Jul 9, 2013
P1, N=20, Recruiting, Sponsor: NPM Pharma Inc.
- Enrollment change: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=180 --> 0
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Jun 30, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
N=180 --> 0 Active, not recruiting --> Completed
- cytarabine / Generic mfg.
Enrollment change: Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=20 --> 10
- Enrollment change, Metastases: Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=20 --> 10 N=528 --> 0
- || Mepact (mifamurtide) / Takeda
Enrollment change: Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=205, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=528 --> 0 N=100 --> 205
- ||| Mepact (mifamurtide) / Takeda
Trial completion: Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=205, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=100 --> 205 Active, not recruiting --> Completed
- Trial withdrawal: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Withdrawn N=36 --> 0
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Jun 12, 2013
P2, N=38, Completed, Sponsor: Amgen
N=36 --> 0 Active, not recruiting --> Completed
- ||| Biomarker, Enrollment open: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=1650, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial withdrawal: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- Enrollment change: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Withdrawn N=35 --> 0
- zoledronic acid / Generic mfg.
Enrollment change, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
N=35 --> 0 N=30 --> 24
- Trial termination: Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: (clinicaltrials.gov) - May 28, 2013
P=N/A, N=8, Terminated, Sponsor: State University of New York - Upstate Medical University
N=30 --> 24 Enrolling by invitation --> Terminated; low enrollment low enrollment
- Enrollment closed, Biopsy: Huntsman Biopsy Study (clinicaltrials.gov) - May 28, 2013
P=N/A, N=100, Active, not recruiting, Sponsor: State University of New York - Upstate Medical University
Enrolling by invitation --> Terminated; low enrollment low enrollment Recruiting --> Active, not recruiting
- | Trial completion, Trial initiation date: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Initiation date: Apr 2002 --> Apr 2005 | Recruiting --> Completed
- Enrollment change: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2002 --> Apr 2005 | Recruiting --> Completed N=65 --> 17
- | Trial completion: Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (clinicaltrials.gov) - May 28, 2013
P=N/A, N=17, Completed, Sponsor: Children's Oncology Group
N=65 --> 17 Recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Enrollment change: COG-AOST0221: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma (clinicaltrials.gov) - Apr 29, 2013
P2, N=49, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed N=40 --> 49
- || Enrollment change: Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma (clinicaltrials.gov) - Apr 29, 2013
P=N/A, N=637, Completed, Sponsor: Children's Oncology Group
N=40 --> 49 N=470 --> 637
- arsenic trioxide / Generic mfg.
Enrollment change, Metastases: Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors (clinicaltrials.gov) - Apr 15, 2013
P2, N=22, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=470 --> 637 N=120 --> 22
- Promacta (eltrombopag) / Novartis
Trial termination, Metastases: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=1, Terminated, Sponsor: Duke University
N=120 --> 22 Enrolling by invitation --> Terminated; Unable to accrue subjects to the study.
- Promacta (eltrombopag) / Novartis
Enrollment change, Metastases: Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=1, Terminated, Sponsor: Duke University
Enrolling by invitation --> Terminated; Unable to accrue subjects to the study. N=60 --> 1
- | everolimus / Generic mfg.
New P2 trial, Metastases: RAD001 in Advanced Sarcoma (clinicaltrials.gov) - Apr 10, 2013
P2, N=41, Completed, Sponsor: Asan Medical Center
- sorafenib / Generic mfg.
Trial completion: Sorafenib in Relapsed High Grade Osteosarcoma (clinicaltrials.gov) - Mar 25, 2013
P2, N=35, Completed, Sponsor: Italian Sarcoma Group
N=60 --> 1 Recruiting --> Completed
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (clinicaltrials.gov) - Mar 19, 2013
P2, N=52, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed N=102 --> 52
- Mepact (mifamurtide) / Takeda
Trial initiation date: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma (clinicaltrials.gov) - Mar 11, 2013
P=N/A, N=25, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=102 --> 52 Initiation date: Oct 2010 --> Dec 2011
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Oct 2010 --> Dec 2011 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
New P2 trial: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Mar 3, 2013
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment change: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Feb 12, 2013
P1, N=6, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
Active, not recruiting --> Recruiting N=15 --> 6
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Enrollment closed: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Feb 12, 2013
P1, N=6, Active, not recruiting, Sponsor: Jennerex Biotherapeutics
N=15 --> 6 Recruiting --> Active, not recruiting
- docetaxel / Generic mfg.
Trial completion: Docetaxel in Treating Children With Recurrent Solid Tumors (clinicaltrials.gov) - Feb 3, 2013
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (clinicaltrials.gov) - Jan 16, 2013
P3, N=711, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed